BG
Bellevue Group Portfolio holdings
AUM
$4.54B
This Quarter Return
+3.83%
1 Year Return
+22.5%
3 Year Return
+98.22%
5 Year Return
+159.37%
10 Year Return
–
AUM
$6.15B
AUM Growth
+$6.15B
(-6.1%)
Cap. Flow
-$279M
Cap. Flow
% of AUM
-4.53%
Top 10 Holdings %
Top 10 Hldgs %
39.96%
Holding
178
New
9
Increased
65
Reduced
60
Closed
12
Top Buys
| 1 |
Stryker
SYK
|
$32.9M |
| 2 |
Biohaven
BHVN
|
$30.9M |
| 3 |
UnitedHealth
UNH
|
$29M |
| 4 |
Insulet
PODD
|
$28.6M |
| 5 |
Regeneron Pharmaceuticals
REGN
|
$26.5M |
Top Sells
| 1 |
Insmed
INSM
|
$75M |
| 2 |
Intuitive Surgical
ISRG
|
$63.3M |
| 3 |
argenx
ARGX
|
$51.2M |
| 4 |
Boston Scientific
BSX
|
$44.6M |
| 5 |
Humana
HUM
|
$40M |
Sector Composition
| 1 | Healthcare | 99.91% |
| 2 | Industrials | 0.05% |
| 3 | Communication Services | 0.02% |
| 4 | Technology | 0.02% |
| 5 | Consumer Discretionary | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
BPMC
126
DELISTED
Blueprint Medicines
BPMC
| $550K | 0.01% |
5,100
| – | – |
|
127
Rhythm Pharmaceuticals
RYTM
$6.75B
| $534K | 0.01% |
13,000
+500
| +4% | +$20.5K |
|
128
Protagonist Therapeutics
PTGX
$3.62B
| $525K | 0.01% |
15,146
-4,000
| -21% | -$139K |
|
129
Zoetis
ZTS
$67.6B
| $510K | 0.01% |
2,941
-4,569
| -61% | -$792K |
|
130
Apple
AAPL
$3.54T
| $463K | 0.01% |
2,200
| – | – |
|
131
Alkermes
ALKS
$4.95B
| $434K | 0.01% |
18,000
-6,144
| -25% | -$148K |
|
132
Rocket Pharmaceuticals
RCKT
$358M
| $424K | 0.01% |
19,700
| – | – |
|
133
Amneal Pharmaceuticals
AMRX
$3B
| $399K | 0.01% |
62,760
+17,373
| +38% | +$110K |
|
134
Xenon Pharmaceuticals
XENE
$2.99B
| $398K | 0.01% |
10,200
-3,900
| -28% | -$152K |
|
135
ADMA Biologics
ADMA
$4.03B
| $345K | 0.01% |
30,900
-10,000
| -24% | -$112K |
|
136
4D Molecular Therapeutics
FDMT
$302M
| $330K | 0.01% |
15,700
| – | – |
|
137
BridgeBio Pharma
BBIO
$9.91B
| $324K | 0.01% |
12,800
| – | – |
|
|
BCYC
138
Bicycle Therapeutics
BCYC
$492M
| $324K | 0.01% |
16,000
+3,500
| +28% | +$70.8K |
|
139
Dynavax Technologies
DVAX
$1.19B
| $309K | 0.01% |
27,558
| – | – |
|
140
Madrigal Pharmaceuticals
MDGL
$9.7B
| $308K | 0.01% |
1,100
+40
| +4% | +$11.2K |
|
141
Viatris
VTRS
$12.3B
| $282K | ﹤0.01% |
26,531
+12,016
| +83% | +$128K |
|
142
C4 Therapeutics
CCCC
$182M
| $266K | ﹤0.01% |
57,600
| – | – |
|
143
Nike
NKE
$110B
| $264K | ﹤0.01% |
+3,500
| New | +$264K |
|
144
Viking Therapeutics
VKTX
$3.02B
| $233K | ﹤0.01% |
4,400
-1,000
| -19% | -$53K |
|
145
Kura Oncology
KURA
$732M
| $206K | ﹤0.01% |
+10,000
| New | +$206K |
|
146
Mineralys Therapeutics
MLYS
$1.94B
| $205K | ﹤0.01% |
17,499
+8,299
| +90% | +$97.1K |
|
147
IDEAYA Biosciences
IDYA
$2.26B
| $200K | ﹤0.01% |
5,700
+2,400
| +73% | +$84.3K |
|
148
89bio
ETNB
$1.37B
| $198K | ﹤0.01% |
24,700
+11,000
| +80% | +$88.1K |
|
149
MoonLake Immunotherapeutics
MLTX
$3.78B
| $193K | ﹤0.01% |
4,400
| – | – |
|
|
TEM
150
Tempus AI, Inc. Class A Common Stock
TEM
$13.3B
| $175K | ﹤0.01% |
+5,000
| New | +$175K |
|